Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
Corporate Deck January 2021
JPM Presentation Jan 14, 2021
Investor Deck December 2020
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Corporate Deck September 2020
Corporate Deck August 2020
Press Releases
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
press release
March 24, 2016
Geneva, Switzerland, 24 March 2016 – ObsEva, a Swiss biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics, today announced…
Read moreObsEva Closes CHF 60 (USD 60) Million in Series B Financing
press release
November 23, 2015
Geneva, Switzerland, 23 November 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising…
Read moreObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis
press release
November 20, 2015
Geneva, Switzerland, 20 November 2015 – ObsEva and Kissei Pharmaceutical Co., Ltd. (“Kissei”) today announced that they have entered into a…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2020
June 9, 2020
ObsEva Annual General Meeting 2019
May 8, 2019
Upcoming Events
ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 – 14, 2021
Event
January 31, 2021
Stock Information
Latest Press Release
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
– European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 – Phase 3 EDELWEISS…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media Switzerland & Europe
Shauna Dillon
+41 (0)22 552 1550 Office
+41 79 360 3533 Mobile
Media United States
Shauna Dillon
+41 (0)22 552 1550 Office
+41 (0)79 360 3533 Mobile
Sign up for news
